Related Topics
 

Non-Therapeutic Protocol

WARPG: Warfarin Pharmacogenetics In Pediatric Patients: Development And Testing Of a Pharmacogenetic–Based Dosing Algorithm

Type of Protocol/Clinical Study

Associated Hematology Studies

Description

This study focuses on learning information from the genetic material and data collection to help develop new guidelines and to improve the method for calculating the correct Coumadin dose for children.

Coumadin is a blood thinner that is taken by mouth. It prevents blood clots by blocking the action of certain clotting factors in the blood. Although Coumadin works very well, like many medications, side effects are possible. In the case of Coumadin, too much of the drug can cause bleeding problems while too little of the drug increases the risk for blood clots. Based on recent research in adult patients, it is known that certain inherited factors cause different people to break down the drug in the body differently; this results in the need for different doses of Coumadin for each individual person. It is also known that children require different doses than adults. The duration of the study will take place for 5 years.


Objectives


Eligibility

Principal Investigator

Ulrike Reiss, MD

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.